Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
نویسندگان
چکیده
Objectives IVAN and TANDEM are factorial randomised controlled trials (RCTs) of different treatment regimens for wet AMD, involving off-label use of bevacizumab. Safety data are being collected but, given follow-up visits every 4-8 weeks for up to 3 years and verbatim reporting, are difficult to collate. We have developed a database solution for the TANDEM trial to minimise duplicate adverse events or events without resolution dates, based on lessons learnt in the IVAN trial.
منابع مشابه
Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration
RATIONALE Aflibercept, an anti-vascular endothelial growth factor (VEGF) drug, is used for treatment of colon cancer as well as retinal diseases, including wet age-related macular degeneration (AMD). It is injected into the vitreous cavity of eyes for treatment of AMD. Although vascular suppression-including cardiovascular events-and local infection related to the injection procedure are well-k...
متن کاملCanadian Health Policy
Anti-VEGF Drugs Anti-VEGF drugs are used to treat retinal conditions such as the wet form of age-related macular degeneration (wAMD) which is responsible for 80-90% of the vision loss associated with AMD. Avastin, Lucentis and Eylea are anti-VEGF drugs. Avastin was developed as a systemic treatment for cancer. It was also considered for retinal conditions, but evidence showed that systemic expo...
متن کاملAnti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach
Pegaptanib (Eyetech Pharmaceuticals and Pfizer), which was approved by the FDA at the end of 2004, was the first anti-VEGF therapy for neovascular AMD (3). After approval of bevacizumab (Genentech/ Roche) for cancer therapy and in view of the suspected role of VEGF in wet AMD, systemic intravenous and, later, intravitreal bevacizumab began to be administered off-label to treat neovascular AMD (...
متن کاملClinical update: new treatments for age-related macular degeneration.
Age-related macular degeneration (AMD) is the leading cause of vision loss in the developed world. Until recently, this condition was believed to be largely untreatable, but developments in the past 2 years have challenged this view. A new class of drugs—based on suppression of vascular endothelial growth factor (VEGF)—has been introduced for the treatment of “wet” or neovascular AMD, the most ...
متن کاملRecent advances in the management and understanding of macular degeneration
Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD.
متن کامل